cyrilzakka/clinical-trials huggingface dataset:
Home Accidents Among Turkish Older Men and Women

Background: Home accidents are a significant public health issue in developed and developing countries. The present study aims to identify the factors associated with home accidents among older individuals in Türkiye.

Methods: Microdata obtained from the Türkiye Health Survey conducted by the Turkish Statistical Institute (TUIK) in 2019 and 2022 were utilized in the present study. Binary logistic regression analysis was used to determine factors influencing home accidents.

Home accidents are a significant public health issue in developed and developing countries. Home refers to where older individuals spend most of their daily time, thus increasing their likelihood of experiencing any accidents at home. Home accidents are more common among older individuals and can lead to serious health consequences. Individuals aged 65 and above are particularly at high risk of home accidents due to physical, psychological, and social impairments. Musculoskeletal problems and sensory and motor function loss in this group increase the risk of accidents. Home accidents are assumed to be unintentional and can range from minor injuries to fatalities. These accidents can occur within the home and in surrounding areas such as garages, gardens, terraces, and stairs. While unintentional home and recreational injuries pose a risk for individuals aged 85 and older, outdoor injuries also pose a risk for younger, older individuals.

Eligibility Criteria:
Inclusion Criteria:

* Older individuals are at risk for home accidents due to their developmental characteristics

Exclusion Criteria:

- healthy volunteers
A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.


Eligibility Criteria:
Inclusion Criteria:

* Males and females in good health, ages 20-40, with no history of pneumococcal vaccination

Exclusion Criteria:

* Subjects with a recent febrile illness
* Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy
Study of Patients With Knee Prostheses Treated With Noninvasive Neuromodulation

It will consist of a randomized clinical trial with a control group. The sample will be distributed as homogeneously as possible into two groups, which will be randomly divided into a control group, to which the usual general treatment will be applied, and an experimental group, which will be treated with the NESA XSignal device. During the procedure, the subjects will continue to receive the usual care routine.

The main objective will be to evaluate the efficacy of the NESA XSignal device in relation to the improvement of pain, functionality and quality of life in patients who have undergone total knee replacement surgery.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years of age
* Total knee replacement surgery at the Hospital San Juan de Dios de Tenerife.
* Be able to freely consent to take part in the study.

Exclusion Criteria:

* No contraindications for treatment with NXSignal: pacemakers, internal bleeding, poor skin condition with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or electricity phobia.
* Patients with total knee prosthesis of more than 3 months of evolution.
* Patients with total knee prosthesis with complications.
Subcutaneous Nitroglycerin for Pediatric Radial Artery Cannulation

The primary objective of the study is to evaluate the vasodilative effect of subcutaneous nitroglycerin during ultrasound-guided radial artery cannulation in pediatric patients. The hypothesis of this study is that the subcutaneous nitroglycerin will increase the radial artery size and improve the first-attempt success rate of radial artery cannulation. This is a single-center, double-blind, randomized, placebo-controlled study comparing the effect of subcutaneous nitroglycerin and saline on radial artery cannulation in pediatric patients undergoing general anesthesia. Prior to the procedure, each patient will be randomized into either the control arm, saline, or study arm, nitroglycerin.


Eligibility Criteria:
Inclusion Criteria:

* General anesthesia
* Arterial cannulation for hemodynamic monitoring, multiple blood sample

Exclusion Criteria:

* Hypersensitivity or contraindication to nitroglycerine
* Unstable vital sign, significant arrhythmia or hypotension, Shock
* High risk of peripheral ischemia
* Skin disease, infection, hematoma, recent cannulation at radial artery.
* Increased intracranial pressure, Intracranial hemorrhage
* Glaucoma
* Recent use of PDE5 inhibitors (\<24 hours after sildenafil or vardenafil; \<48 hours after tadalafil)
A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport

To develop a cancer center level practice intervention to promote treatment adherence and reduce outcome disparities in pediatric cancer survivors

To conduct a pilot study to assess the feasibility and acceptability of the Social Determinants of Adherence intervention

Eligibility Criteria:
Inclusion Criteria:

Parents/caregivers of pediatric patients must meet the following criteria to be eligible:

* Parents/guardians of child that has been diagnosed with any cancer.
* Parents/guardians of child with any cancer between age 0 and 18.
* Parents/guardians of child on home-based oral anti-cancer therapy or supportive care therapy.
* The clinician for the family agrees to participate in the study.

Exclusion Criteria:

* Participants will be excluded from this study if unwilling or unable to complete the assessment in English
Iron Overload in Pediatric Oncology Patients

The purpose of this study is to evaluate for iron overload in pediatric oncology and transplant patients who have completed their treatment between one to ten years ago.

Long term survivors of childhood cancer, are a distinct group requiring specific follow-up in order to enhance their quality of life. Studies have shown that many of these patients will go on to develop chronic issues within different organ systems. Because of the iron burden of the frequent transfusions required to care for these patients, iron overload may indeed be one of the problems these survivors potentially face. Research primarily in thalassemia and bone marrow transplant patients who were extensively transfused has shown that iron overload can have a significant impact on their overall health. Complications from increased iron burden can include growth retardation, gonadal dysfunction, hypothyroidism, impaired glucose metabolism, cardiac arrhythmias and failure, hepatic fibrosis and cirrhosis, and increased susceptibility to infections. However all of these conditions related to iron overload can be prevented with the use of either phlebotomy or chelation therapy. Based on this knowledge, our objective is to determine if pediatric oncology and transplant patients heavily supported with transfusions develop consequential biochemical and clinical evidence of iron overload.

Eligibility Criteria:
Inclusion Criteria:

* Patients six and a half to twenty five years of age with a history of acute myelogenous leukemia, rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, and neuroblastoma who have completed their treatment or received their last packed red blood cell transfusion at least one year prior to enrollment (which ever occurred later) and are one to ten years post-treatment.
* Patients six and a half to twenty five years of age who have undergone hematopoietic stem cell transplant for any malignancy and are at least one year from their last transfusion or transplant date prior to enrollment (which ever occurred later) and are one to ten years post-transplant.
* Patients who were treated at Schneider Children's Hospital or at Children's Hospital of Philadelphia.

Exclusion Criteria:

* Patients who have clinical evidence of chronic graft vs. host disease of skin, liver or gastrointestinal tract.
* Patients with a chronic infection (viral hepatitis), liver disease (fibrosis, cirrhosis), or a history of radiation to the liver.
* Patients who cannot have an MRI due to metallic implants (i.e. pacemakers, prosthetic valves, etc.)
* Patients who are pregnant.
Effect of Belimumab on Antibody Titers in Primary APS Patients

The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.

This is a single center, randomized controlled trial in Ruijin Hospital. The enrolled patients will be randomized in a 1: 1 ratio to receive either SOC+Belimumab or SOC treatment. Belimumab is administered intravenously at a dose of 10mg/kg once a month for 18 months.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years old.
* Positive for high-titer antiphospholipid antibodies according to the criteria of the "EULAR Guidelines for the Treatment of Antiphospholipid Syndrome in Adults" published in 2019.
* Stable APS regimen according to EULAR recommendations for antiphospholipid syndrome.
* Female patients who are not pregnant, breastfeeding, of childbearing potential, or not using contraception.

Exclusion Criteria:

* Patients with a history of malignant tumor in the past 5 years, except for basal cell carcinoma or squamous cell carcinoma of skin or cervical carcinoma in situ treated locally, and there is no evidence of metastasis within 3 years;
* Patients with a history of primary immunodeficiency;
* Serious lack of IgG (IgG level \&lt; 400 mg/dL);
* IgA deficiency (IgA level \&lt; 10 mg/dL);
* Patients with a current history of infection;
* Patients with a current history of drug or alcohol abuse or dependence, or have a history of drug or alcohol abuse or dependence within 365 days before day 0;
* HIV test is historically positive or HIV screening is positive;
* Hepatitis status;
* Patients with a history of allergic reaction caused by injection of contrast agent, human or mouse protein or monoclonal antibody;
* Patients with other abnormal laboratory values with clinical significance;
* If women with reproductive potential (WCBP) are included, please refer to the following special instructions;
* Patients with concurrent major medical or mental illnesss;
* Patients with diseases of liver, kidney, heart and other important organs,blood and Endocrine system;
* Patients who have been vaccinated with live vaccine in the last month;
* Patients who have participated in any clinical trial within 28 days before the initial screening and/or within 5 times of the half-life of the study compound (whichever is longer);
* Patients who use B-cell targeted therapy drugs within one year, such as rituximab or epratuzumab;
* Patients who use tumor necrosis factor inhibitor and interleukin receptor blocker within one year;
* Patients who use Intravenous gamma globulin (IVIG) and prednisone ≥100mg/d for more than 14 days within one year or plasma exchange;
* Patients with active infection (such as herpes zoster, HIV infection, active tuberculosis, etc.) during the screening period;
* Patients with depression or suicidal thoughts;
* Other conditions that the investigator considers would make the candidate unsuitable for the study.
PERINE : Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain : an MRI Study

This project aims at evaluating the consequences of prenatal exposure to neurotoxicants (solvents, organophosphate pesticides) on the developing brain, in children aged from 10 to 12 years.


Eligibility Criteria:
Inclusion Criteria:

* Children included in the cohort PELAGIE
* Children participated in the study PEPSY
* Age between 10 and 12 years (pilot study)

Exclusion Criteria:

* Maternal smoking and or alcohol consumption during pregnancy (study group)
* Children with a health event affecting neurodevelopment
* Children treated with methylphenidate, psychotropic or anti-epileptics
Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers

The purpose of this study is to evaluate the safety and pharmacodynamics of SEL-068. Increasing subcutaneous doses of SEL-068 will be administered to healthy non-smoker and smoker volunteers. The resulting safety profile and anti-nicotine antibody levels will be evaluated.


Eligibility Criteria:
Primary Inclusion Criteria:

* Healthy Smokers
* Healthy non-smokers
* Written informed consent

Primary Exclusion Criteria:

* Prior exposure to nicotine vaccines
* Female subjects of childbearing potential
* Current use of immunosuppressive agents
* History of or current autoimmune disorder of immunosuppressive condition (e.g. HIV infection)
* Concurrent participation or participation within 8 weeks prior to the initial study drug administration in a drug/device or biologic investigational research study.
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age

This is an observational post-marketing study conducted in children and adults immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites.

Children and adults will be immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites. Using existing data on healthcare utilization, rates of medically attended events (MAEs) of interest will be evaluated in all eligible Q/LAIV recipients who are vaccinated in the Kaiser Permanente (KP) Northern California Health Care Plan during the 2013-2014 influenza season. Enrollment must include a minimum of 10,000 children 2 through 8 years of age; based on previous utilization of FluMist at NCKP, enrollment is expected to include approximately 80,000 children and adults 2 to 49 years of age.

Eligibility Criteria:
Inclusion Criteria:

1. . Age 2 through 49 years at the time of vaccination (or index date for unvaccinated controls)
2. . Membership in the KP Health Care Plan for at least 12 months prior to vaccination/index date
3. . Continuous enrollment in KP Health Care Plan through 6 months following vaccination/index date.

Exclusion Criteria:

NONE
A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery

The aim of the study is to compare different strategies for prevention of venous thromboembolism related to intracranial meningioma surgery. The investigators identified three hospitals where two have a very restrictive approach with respect to anticoagulant therapy while at the third hospital the use of anticoagulation the day before surgery was initiated as routine prophylaxis.

Based on this "natural experiment" it will be explored whether the use of anticoagulant prophylaxis is associated with reduced risk of venous thromboembolism and/or associated with increased risk of postoperative hemorrhage as compared to the 2 cohorts where this intervention were absent.


Eligibility Criteria:
Inclusion Criteria:

* First included patient 1.january 2007 and latest included patient 1.july 2013 (allows for 30 day follow up with respect to morbidity)
* Histological verification of a meningioma (of any grade) from the current surgery

Exclusion Criteria:

* Intracranial surgery or venous thromboembolism the last 3 months
Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

This study seeks to determine if photobiomodulation (PBM, or low level laser light) affects the growth and distribution of nerves int he skin. Our previous study demonstrated that the treatment we use here was effective at reducing the symptoms of neuropathy (as measured by the modified total neuropathy score) in patients who had been treated with chemotherapy. The current effort is designed to repeat this confirm this observation using a more extensive battery of survey as well as to begin to elucidate the mechanism through which photobiomodulaiton produces the effect. WE will also be attempting to determine if diabetic patients differ in terms of response from chemotherapy patients

Consenting patients with self-reported neuropathy following either diabetes or administration of chemotherapy, will undergo sensory testing and skin biopsies of the the foot and leg prior to initiating treatment. They will undergo PBM 3 times weekly for 6 weeks with with a follow-up biopsy performed at the conclusion of therapy and sensory testing throughout. Patients will have one remote evaluation at 26 weeks to determine whether the effect, if any extinguishes.

Eligibility Criteria:
Inclusion Criteria: self reported neuropathy following exposure to diabetes or chemotherapy

* willingness to undergo biopsies and 6 weeks of therapy

Exclusion Criteria:

* pregnancy
* active cancer treatment
Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.


Eligibility Criteria:
Inclusion Criteria:

* Non-pregnant, non-lactating female outpatients between the ages of 18 - 44 years (inclusive)
* Patients with at least two of the following clinical signs and symptoms of an uUTI:

  * Dysuria
  * Frequency
  * Urgency
  * Suprapubic pain
* Patients with onset of symptoms \< 72 hours prior to study entry
* Patients with one positive pre-treatment clean-catch midstream urine culture at enrollment in the study, defined as \> 10000 CFU/mL (study drug treatment is permitted prior to the availability of urine culture results)
* Positive leukocyte esterase (LE) (1+ or greater) utilizing a urine dipstick method of analysis
* Patients willing to give written informed consent
* Cultures must be performed on pre-treatment clean-catch midstream urine (MSU) specimens

Exclusion Criteria:

* Males
* Women who are pregnant, nursing, or not using two medically accepted, effective methods of birth control
* Patients with known or suspected hypersensitivity to quinolones
* Patients unable to take oral medication for any reason
* Patients with an asymptomatic bacteriuria
* Patients with complicated UTI, defined as: a clinical syndrome characterized by the development of systemic and local signs and symptoms of fever (\> 38.3°C/101°F orally), chills, malaise, flank pain, back pain, or costovertebral angle (CVA) pain or tenderness
* Symptoms as outlined in the inclusion criteria occurring in the presence of a functional or anatomical abnormality of the urinary tract or in the presence of urinary catheterization
* Patients with symptoms of a UTI within the 4 weeks prior to the present episode
* Patients with the onset of symptoms \>72 hours prior to study entry
* Patients with three or more episodes of any UTI in the past 12 months
* Patients with evidence of factors predisposing to the development of UTIs, including calculi, stricture, primary renal disease (e.g. polycystic renal disease), or neurogenic bladder
* Patients who received systemic antimicrobial therapy within 48 hours prior to entry
* Patients with a neutrophil count \< 1000/mm3, CD4 \< 200/mm3 or other conditions associated with significant depression in host defense; HIV testing is not mandatory
* Patients requiring concomitant systemic antibacterial therapy with agents not specified in this protocol
* Patients with a previous history of tendinopathy associated with fluoroquinolones
* Patients diagnosed with a rapidly fatal underlying disease (death expected within six months)
* Patients requiring concomitant use of theophylline
* Patients previously enrolled in this clinical study
* Patients taking an investigational drug in the last 30 days
Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI

Purpose: The investigators team recently carried out a proof of concept study testing the efficacy of one single 45-minute session of 10 Hz TENS prior to walking, versus placebo. In this randomized study, the investigators found that TENS significantly delayed pain onset and increased the pain-free walking distance in patients with class II PAD. From these encouraging results, the investigators now seek to assess the efficacy of an intervention that includes the daily use of TENS for 3 weeks (5 days a week) on walking distance in PAD (Leriche-Fontaine stage II). Methods/Design: prospective multicentre study / randomized controlled trial / double blinding.

Interventions (2 groups): Experimental group (TENS group): the treatment will consist of stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week. Control group (group SHAM): the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.

15 days of interventions (TENS or SHAM) between J0 and J23, End of study for patient at J24-J25, two days for the last analyses who are the same of inclusion's visit J0.

Primary outcome: walking distance (metres) measured on a treadmill with a standardized protocol. Secondary outcomes: transcutaneous oxygen pressure (TcPO2) measured during a Strandness exercise test, peak oxygen uptake (VO2 peak) (ml.min.kg-1), endothelial function (EndoPAT®), ankle-brachial pressure index, body mass index, lipid profile (LDL-C, HDL-C, Triglycerides), fasting glycaemia, HbA1c, WELCH questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Unilateral Leriche stage II PAD, admitted to cardiovascular Rehabilitation Unit
* Men or women
* Able to take part in an out-patient rehabilitation programme
* Clinically stable
* Sedentary
* Provided informed consent to participate in the study

Exclusion Criteria:

* Ward of court
* Walking disorders related to orthopaedic or neuromuscular disease
* Participation in a structured physical reconditioning programme in the month before the study
* Renal insufficiency requiring dialysis
* Known and documented myopathy
* Progressive cancer
* Associated progressive disease causing a deterioration in general health
* Participation in another research protocol
* Skin disorder making it impossible to use TENS
* Absolute contra-indication to physical activity
* Presence of pacemaker / defibrillator
* Pregnant women in the 1st trimester / 12 weeks
Markers of Executive Attention Development in Preschoolers

This project aims to identify precursors of executive attention that can serve as early markers of ADD.


Eligibility Criteria:
Inclusion Criteria:

* Normal schooling
* Parental consent

Exclusion Criteria:

- Psychotropic drug